Effects of Inclisiran in Patients With Atherosclerotic Cardiovascular Disease

ObjectiveTo evaluate the efficacy, safety, and tolerability of inclisiran in participants with atherosclerotic cardiovascular disease (ASCVD) from ORION-10 and ORION-11 stratified by key patient characteristics.Patients and MethodsParticipants were randomized 1:1 to receive 300 mg inclisiran sodium (284 mg inclisiran) or placebo on Days 1, 90, 270, and 450, alongside background lipid-lowering therapy. This pooled, post hoc analysis stratified participants with ASCVD by sex, age, race, kidney function, body mass index, and glycemic status. Co-primary endpoints were percentage changes in low-density lipoprotein cholesterol (LDL-C) from baseline to Day 510, and after Day 90 and up to Day 540 (time-adjusted). LDL-C goal attainment and safety were also assessed.ResultsThis analysis of 2975 participants included: female, n=827; Black, n=213; 75 years of age or older, n=458; obese, n=1474; diabetes, n=1182; and moderate-to-severe chronic kidney disease, n=538. Mean baseline LDL-C levels in the total ASCVD population were balanced between treatment arms (inclisiran, 103.4 mg/dL; placebo, 102.0 mg/dL). With inclisiran, mean placebo-corrected percentage changes in LDL-C from baseline were −51.5% (95% CI, −54.0 to −49.0) and −52.1% (95% CI, −53.9 to −50.4) to Day 510 and Day 540 (time-adjusted), respectively; this was consistent across subgroups. LDL-C less than 55 mg/dL at one or more visits was reached by 87.6% of participants receiving inclisiran. The inclisiran safety profile was consistent across subgroups.ConclusionTwice-yearly inclisiran (after initial and 3-month doses) was well tolerated and provided significant, consistent LDL-C reductions for up to 18 months in participants with ASCVD independent of key patient characteristics (ORION-10; NCT03399370 and ORION-11; NCT03400800).